AZD-3514

WARNING: This product is for research use only, not for human or veterinary use.

Description:AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. AZD3514 is being evaluated in a Phase I clinical trial in patients with castrate-resistant prostate cancer.

Price and Availability

AZD-3514,is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 204540Name: AZD-3514CAS#: 1240299-33-5Chemical Formula: C25H32F3N7O2Exact Mass: 519.25696Molecular Weight: 519.56Elemental Analysis: C, 57.79; H, 6.21; F, 10.97; N, 18.87; O, 6.16

Synonym:AZD3514; AZD 3514; AZD-3514.

IUPAC/Chemical Name:1-(4-(2-(4-(1-(3-(trifluoromethyl)-7,8-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)piperazin-1-yl)ethanone

InChi Key:JMEYDSHPKCSIJC-UHFFFAOYSA-N

InChi Code:InChI=1S/C25H32F3N7O2/c1-18(36)33-14-12-32(13-15-33)16-17-37-21-4-2-19(3-5-21)20-8-10-34(11-9-20)23-7-6-22-29-30-24(25(26,27)28)35(22)31-23/h2-5,20H,6-17H2,1H3

SMILES Code:CC(N1CCN(CCOC2=CC=C(C3CCN(C4=NN5C(CC4)=NN=C5C(F)(F)F)CC3)C=C2)CC1)=O

Technical Data

Additional Information

AZD3514 is currently in Phase I trail. This trial is looking at a new drug called AZD3514 for men who have prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy.  Doctors often use hormone therapy to treat prostate cancer. This may keep it under control for long periods of time. But researchers are looking for treatments that will help men who have prostate cancer that stops responding to hormone therapy.  Prostate cancer needs the hormone testosterone to grow. The testosterone locks into receptors on the cancer cells. AZD3514 works by breaking down these receptors so that testosterone canÂ’t tell the prostate cancer cells to grow.  

References

1: Bradbury RH, Acton DG, Broadbent NL, Brooks AN,Carr GR, Hatter G, Hayter BR,  Hill KJ, Howe NJ, Jones RD, Jude D,Lamont SG, Loddick SA, McFarland HL, Parveen  Z, Rabow AA,Sharma-Singh G, Stratton NC, Thomason AG, Trueman D, Walker GE, WellsSL, Wilson J, Wood JM. Discovery of AZD3514, a small-molecule androgenreceptor downregulator for treatment of advanced prostate cancer. BioorgMed Chem Lett. 2013 Apr 1;23(7):1945-8. doi: 10.1016/j.bmcl.2013.02.056.Epub 2013 Feb 21. PubMed PMID: 23466225.